Disease relevance of Facial Pain

• The circadian periodicity of some endocrine (PRL, cortisol, GH) and vegetative (oral temperature, blood pressure) functions has been studied in cluster headache, common migraine, atypical facial pain, and "mixed" headache [1].
• The first patient had retroauricular pain, simvastatin-induced myopathy and subclinical axonal peripheral neuropathy; the second patient had a post-viral benign sensory neuropathy; and the third had retroauricular and facial pain and no underlying neurological illness [2].
• The selective COX-2 inhibitors hold promise for clinical efficacy with less toxicity from chronic administration and may prove advantageous for the relief of chronic orofacial pain [3].
• Percutaneous retrogasserian glycerol rhizolysis was ineffective in relieving atypical trigeminal neuralgia or atypical facial pain [4].
• METHODS: The Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) data for Axes I and II for 196 consecutive patients (56 men and 140 women) with a history of facial pain were obtained [5].

Psychiatry related information on Facial Pain

• The presence of increased blinking with facial pain, dystonic movements, and other facial movements at each neuroleptic dose reduction pointed toward withdrawal dystonia rather than toward a worsening of Tourette's disorder [6].
• Behavior modification and haloperidol in chronic facial pain [7].

High impact information on Facial Pain

• Octreotide relieved facial pain but did not alter tumor progression [8].
• Midline sensory complaints and facial pain are uncommon [9].
• T injection was followed by severe headache, facial pain, and increase in PRL to 13,471 ng/ml [10].
• In order to examine the effect of estrogen on facial pain, we first compared the face-rubbing evoked by a formalin injection in the lip of aromatase-knockout (ArKO) mice, lacking endogenous estrogen production, 17 beta-estradiol-treated ArKO mice (ArKO-E2) and wild-type (WT) littermates [11].
• These results indicate that cannabinoid receptor agonists may be effective agents for craniofacial pain [12].

Chemical compound and disease context of Facial Pain

• Antihyperalgesic activity of epibatidine in the formalin model of facial pain [13].
• Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain [14].
• The NMDA antagonist Memantine blocks pain behavior in a rat model of formalin-induced facial pain [15].
• In seven patients with atypical facial pain, striatal presynaptic dopaminergic function was assessed with [18F]FDOPA and dopamine D1 and D2 receptor availabilities with [11C]NNC 756 and [11C]raclopride, respectively [16].
• The results showed some moderately to strongly stained glutamate receptor 1 neurons, and many strongly stained glutamate receptor 2/3 neurons in lamina II of the nucleus, suggesting that the latter may play an important role in orofacial pain processing, with the former playing a minor role [17].

Biological context of Facial Pain

• A 37-yr-old man with a 60-mm invasive tumor and a serum PRL level of 13,969 +/- 332 ng/ml (mean +/- SD) responded to BRC therapy with rapid disappearance of visual field defect, headache, and facial pain as well as decrease in serum PRL to 5,103 +/- 1,446 ng/ml [10].
• Acupuncture TMD and facial pain [18].

Anatomical context of Facial Pain

• Erythrocyte catechol-O-methyltransferase activity in facial pain patients [19].
• Atypical facial pain, ectasia of the basilar artery, and baclofen: a case report [20].
• Various clinical indications for imaging each patient with routine radiography, tomography, and surface-coil MR included headache, temporomandibular joint (TMJ) and/or ilsilateral facial pain, joint crepitus, clicking, locking, and either recently acquired or changing (unstable) occlusal disorder [21].
• Since this extension alters both management and prognosis, GdMRI in the coronal plane is a necessary investigation for persistent and unexplained facial pain in order to demonstrate such lesions of the trigeminal nerve [22].
• Postoperative follow-up suggests that the Xylocaine test may be a good prognostic aid for surgical outcome for craniofacial pain of apparent middle turbinate origin [23].

Gene context of Facial Pain

• Altered dopamine D2 receptor binding in atypical facial pain [16].
• Dr. David Jones refutes the Melkonians' support of the AACP application for craniofacial pain specialty [24].
• In addition, proband descriptors of facial pain severity or disability did not significantly predict the likelihood of having a first degree relative with one or more TMD-related symptoms [25].
• Dates of initial onsets of myofascial face pain and MDD in patient probands were obtained from interviews and records [26].
• In two atypical facial pain studies the combined odds ratio for benefit was 4.1 (2.3-7.5), with a NNT of 2.8 (2-4.7) [27].

Analytical, diagnostic and therapeutic context of Facial Pain

• Seven months after treatment onset, a combination of nortriptyline, clonazepam, and relaxation procedures has successfully controlled the patient's facial pain symptoms [28].
• In conclusion, this study points towards some beneficial effect of a single subcutaneous injection of sumatriptan in the treatment of atypical facial pain [29].
• A double-blind, placebo-controlled crossover study was undertaken to assess the efficacy and tolerability of sumatriptan in patients with atypical facial pain [29].
• The aim of this epidemiological study was to investigate the prevalence of facial pain and TMD, their relation to each other, and also their relation to previous traumas, occlusal factors and pain in other areas of the body [30].
• The patient had previously undergone a left tympanoplasty secondary to cholesteatoma and had been treated for atypical face pain with ibuprofen taken every six hours for three months [31].

References